Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 4, 2026, reporting its financial results for the quarter ended June 30, 2026. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set fort…

The filing is about an amendment to the company's incentive plan, not a management change.

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 13, 2026, reporting its financial results for the quarter ended March 31, 2026. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth…

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 25, 2026, reporting its financial results for the year ended December 31, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set for…

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 13, 2025, reporting its financial results for the quarter ended September 30, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly…

Unregistered Sales of Equity Securities. On September 15, 2025, the holders of Precigen, Inc.’s (the “Company’s” and “our”) 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79,000,000) into 54,937,411 shares of common stock of the Company, which were delivered to such holders on September 17, 2025 pursuant to the terms of our Amended and Restated Articles of Incorporation and such Preferred…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

Entry into a Material Definitive Agreement. Pharmakon Loan Agreement On September 3, 2025 (the “ Closing Date ”), Precigen, Inc . (“ we ” or the “ Company ”) and certain of our subsidiaries party thereto as guarantors entered into a loan agreement (the “ Loan Agreement ”) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder (the “ Lenders ”) and BioPharma Credit PLC as the collateral agent, each of which are investment entities managed by Phar…

Entry into a Material Definitive Agreement. On August 13, 2025 (the “Effective Date”), Precigen, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Supply Agreement”) with Catalent Maryland, Inc. (“Catalent”). The Supply Agreement provides that Catalent will perform certain services specified in a Plan Document (as defined in the Supply Agreement) (“Services”) including analytical, development, processing, validation, or product maintenance of PAPIZEMOS (“Product”), subject…

The filing is about an amendment to the company's incentive plan, not a management change.

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2025, reporting its financial results for the quarter ended March 31, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth…

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2025, reporting its financial results for the quarter and year ended December 31, 2024. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expre…

Other Events. On December 27, 2024, Precigen, Inc. (“Precigen”) announced that it had entered into a Securities Purchase Agreement dated December 27, 2024 (the “Purchase Agreement”) with investors, including Randal J. Kirk, its executive chairman of the board of directors, affiliates of Patient Capital Management and Bill Miller, as well as certain other investors (the “Investors”) for the sale of its 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) and warrants (“Warr…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. The information contained in

Material Modification to Rights of Security Holders. The information contained in

Entry into Material Definitive Agreement On December 18, 2024, Precigen, Inc. (“Precigen” or the “Company”), entered into an Asset Acquisition Agreement (the “Acquisition Agreement”) with Innovator 21, LLC (“Buyer”), a Delaware limited liability company and an affiliate of Paragon Biosciences, LLC (“Paragon”), pursuant to which the Company agreed to sell to Buyer certain assets, including intellectual property rights and royalty rights, related to FCX-007, a clinical stage product candidate b…

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 14, 2024, reporting its financial results for the quarter ended September 30, 2024. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 1, 2024, Precigen, Inc. (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), as the minimum bid price for the Company’s listed securities was less than $1 for the previous 30 consecutive business d…

Termination of a Material Definitive Agreement As previously disclosed, on April 3, 2023, Precigen, Inc. (“Precigen” or the “Company”), entered into an Amended and Restated License Agreement (the “A&R License Agreement”) with Alaunos Therapeutics, Inc. (“Alaunos”), which amended and restated in its entirety the License Agreement, dated October 5, 2018, by and among the same parties, for the grant of certain licenses by Precigen to Alaunos. On October 4, 2024, the A&R License Agreement was ter…

Senior Vice President, Intellectual Property Affairs — Jeffrey Perez: Mr. Perez is leaving the company and will receive severance benefits.

The filing describes the grant of performance stock units to certain key employees, including named executive officers.

Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 14, 2024, reporting its financial results for the quarter ended June 30, 2024. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set for…

Entry into a Material Definitive Agreement. On August 7, 2024, Precigen, Inc. (“Precigen”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated, as the representative of the several underwriters named therein (the “Underwriters”), in connection with the underwritten public offering (the “Offering”) of 35,294,118 shares (the “Firm Shares”) of Precigen common stock, no par value (“Common Stock”), at a price to the public of $0.85 pe…

Results of Operations and Financial Condition. Precigen, Inc. (the “Company”) hereby furnishes the estimate that, as of June 30, 2024, the Company’s cash, cash equivalents, and short-term investments were approximately $19.5 million. The information set forth above is preliminary and unaudited and reflects preliminary financial information as of and for the quarter ended June 30, 2024. In preparing this information, the Company’s actual results for the quarter ended June 30, 2024 have not yet…